In this video, I walk you through how to use Riverside to record high-quality interviews and podcasts, with both audio and ...

Replimune received FDA acceptance for its RP1 BLA resubmission in advanced melanoma, with a PDUFA date set for April 2026. REPL stock surged nearly 100% on the news, but FDA acceptance only restarts ...

Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...

Description: 💙 Thank you to JoggAI for sponsoring this video! Join the JoggAI AvatarX Challenge for a chance to win $10,000 ...

The biotech received the good news it was hoping for from a top national regulator. This concerned RP1, its advanced melanoma drug. Well before market open, Replimune announced that the U.S. Food and ...

I am selling my remaining shares in TARS for 90% gain. I am adding to my position in DERM on the dip back to $7. I am initiating a new position in REPL with 5% portfolio weighting. REPL- FDA's ...

Replimune (REPL) Earnings Dates & Reports On this page, you can find detailed information about the financial performance of Replimune Group Inc, including the latest Replimune Group Inc earnings ...

Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...

From how to French brain or play the guitar to how to unclog a sing or perform CPR, you can learn all kinds of useful skills on YouTube. We at Mental Floss are always eager to learn new things and ...

When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. The best website builders not only make creating a website ridiculously easy, many of them also ...

FDA accepted Replimune’s resubmitted Biologics License Application for RP1 combined with Bristol Myers Squibb’s Opdivo to treat advanced melanoma The agency set April 10, 2026 as the decision deadline ...